title: Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding.
abstract: OBJECTIVE
  Despite improvements in chemotherapy and surgical techniques, the prognosis in advanced gastric cancer with peritoneal dissemination still remains very poor. At present, no standard method of treatment has been established for these patients. Therefore, we assessed the feasibility of S-1, a novel oral derivative of 5-fluorouracil, as a postoperative adjuvant chemotherapy for these patients.
  
  
  METHODS
  Seven patients were enrolled for 1 year. All patients underwent macroscopically curative resection (R1) by an aggressive cytoreductive surgery. S-1 was given orally at a dose of 80 mg/m2/day, for 28 consecutive days followed by a 14-day rest, repeated every 6 weeks.
  
  
  RESULTS
  S-1 was administered for 1 year in 3 out of 7 patients, while the treatment was discontinued in 4 patients due to disease progression. The median S-1 1 cycle given was 5. Grade 2 leukopenia was observed in 3 patients and grade 2 elevation of total bilirubin in one patient. All other adverse reactions were grade 1. The median overall survival was > 696 days with a 1-year survival rate of 85.7%. The median overall progression-free survival was 213 days.
  
  
  CONCLUSIONS
  S-1 is feasible as a postoperative adjuvant chemotherapy for resectable gastric cancer with peritoneal seeding.
authors.affiliation: Department of Surgery, Osaka National Hospital, 2-1-14, Hoenzaka, Chuo-ku, Osaka 540-0006, Japan. fujitani@onh.go.jp
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Fujitani
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Tsujinaka
authors.forename: Motohiro
authors.initials: M
authors.lastname: Hirao
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018450:Disease Progression; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009366:Neoplasm Seeding; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid